Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$132.63 -0.4%	$126.65	$110.04 ▼ $238.00	$19.52B	0.14	1.43 million shs	633,328 shs
MU Micron Technology	$122.03 +0.2%	$102.72	$61.54 ▼ $137.13	$136.24B	1.35	23.34 million shs	13.25 million shs
REGN Regeneron Pharmaceuticals	$545.00 -0.5%	$550.54	$476.49 ▼ $1,211.20	$59.14B	0.33	905,431 shs	456,413 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	-0.42%	+4.49%	+0.60%	+7.84%	-40.95%
MU Micron Technology	+0.23%	-3.15%	+19.34%	+88.54%	-10.81%
REGN Regeneron Pharmaceuticals	-0.50%	+4.61%	+11.71%	-4.96%	-46.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.9596 of 5 stars	4.2	5.0	0.0	3.7	3.3	1.7	2.5
MU Micron Technology	4.9585 of 5 stars	3.4	5.0	1.7	1.8	3.8	2.5	3.1
REGN Regeneron Pharmaceuticals	4.9519 of 5 stars	4.4	5.0	1.7	2.3	3.2	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.38	Hold	$188.48	42.12% Upside
MU Micron Technology	2.83	Moderate Buy	$146.21	19.82% Upside
REGN Regeneron Pharmaceuticals	2.80	Moderate Buy	$813.57	49.28% Upside

Current Analyst Ratings Breakdown

Latest MU, REGN, and BIIB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	REGN Regeneron Pharmaceuticals	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/27/2025	MU Micron Technology	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$163.00 ➝ $200.00
6/26/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$187.00
6/26/2025	MU Micron Technology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$150.00 ➝ $165.00
6/26/2025	MU Micron Technology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$145.00 ➝ $155.00
6/26/2025	MU Micron Technology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$120.00 ➝ $150.00
6/26/2025	MU Micron Technology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$98.00 ➝ $135.00
6/26/2025	MU Micron Technology	Susquehanna Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Positive ➝ Positive	$150.00 ➝ $160.00
6/26/2025	MU Micron Technology	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $165.00
6/26/2025	MU Micron Technology	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$84.00 ➝ $140.00
6/26/2025	MU Micron Technology	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$150.00 ➝ $170.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.68B	2.01	$23.03 per share	5.76	$114.71 per share	1.16
MU Micron Technology	$25.11B	5.44	$7.62 per share	16.01	$45.35 per share	2.69
REGN Regeneron Pharmaceuticals	$14.20B	4.14	$45.49 per share	11.98	$268.50 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.13	13.09	8.03	1.06	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
MU Micron Technology	$778M	$4.17	21.99	11.44	N/A	18.41%	13.60%	8.90%	N/A
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	13.87	14.33	2.01	31.94%	15.27%	11.93%	8/1/2025 (Estimated)

Latest MU, REGN, and BIIB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/1/2025	Q2 2025	REGN Regeneron Pharmaceuticals	$8.53	N/A	N/A	N/A	$3.30 billion	N/A
6/25/2025	Q3 2025	MU Micron Technology	$1.57	$1.91	+$0.34	$1.68	$8.83 billion	$9.30 billion
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
MU Micron Technology	$0.46	0.38%	N/A	11.03%	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.65%	N/A	8.96%	N/A

Latest MU, REGN, and BIIB Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	MU Micron Technology	quarterly	$0.1150	0.4%	7/7/2025	7/7/2025	7/22/2025
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.27	1.44	1.01
MU Micron Technology	0.30	2.75	1.89
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
MU Micron Technology	80.84%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.18%
MU Micron Technology	0.30%
REGN Regeneron Pharmaceuticals	7.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
MU Micron Technology	48,000	1.12 billion	1.12 billion	Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable

MU, REGN, and BIIB Headlines

Recent News About These Companies

Vontobel Holding Ltd. Has $4.66 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

2 hours ago | marketbeat.com

Regeneron Scores Multiple Myeloma Nod for Bispecific, Unlocking $600M Opportunity

July 3 at 4:02 PM | biospace.comB

Regeneron’s Pozelimab Study: A New Hope for Rare Disease Patients

July 3 at 12:20 PM | tipranks.com

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

July 3 at 10:20 AM | zacks.com

First Horizon Advisors Inc. Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

July 3 at 7:08 AM | marketbeat.com

Regeneron wins FDA accelerated approval for Lynozyfic in MM

July 3 at 6:46 AM | thepharmaletter.comT

Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA

July 3 at 6:46 AM | msn.com

Regeneron stock rises after FDA approval for blood cancer therapy

July 2 at 3:44 PM | investing.com

Regeneron Shares Climb Following FDA Approval of Blood Cancer Treatment

July 2 at 3:44 PM | msn.com

Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps

July 2 at 3:44 PM | msn.com

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

July 2 at 11:45 AM | wsj.com

US FDA approves Regeneron's blood cancer therapy

July 2 at 11:11 AM | reuters.com

Regeneron Pharmaceuticals Receives FDA Accelerated Approval for Lynozyfic™ in Treating Relapsed or Refractory Multiple Myeloma

July 2 at 11:11 AM | quiverquant.comQ

Regeneron Pharmaceuticals Unusual Options Activity For July 01

July 2 at 10:43 AM | benzinga.com

Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Strong Tailwind

July 2 at 10:43 AM | msn.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

July 2 at 9:56 AM | zacks.com

Sumitomo Mitsui DS Asset Management Company Ltd Sells 2,531 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

July 2 at 6:37 AM | marketbeat.com

Allspring Global Investments Holdings LLC Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

July 2 at 4:31 AM | marketbeat.com

Regeneron and Bayer’s Promising Phase 3 Study on Aflibercept for Diabetic Macular Edema

July 1 at 12:34 PM | tipranks.com

Regeneron and Bayer’s High-Dose Aflibercept Study: Key Insights for Investors

July 1 at 12:34 PM | tipranks.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by New York State Teachers Retirement System

July 1 at 5:18 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
Why Qualcomm’s Latest Price Target Can't Be Ignored
By Sam Quirke | June 24, 2025
View Why Qualcomm’s Latest Price Target Can't Be Ignored
RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
By Ryan Hasson | June 11, 2025
View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
Dollar Down 10%? These 3 Stocks Could Soar
By Chris Markoch | July 1, 2025
View Dollar Down 10%? These 3 Stocks Could Soar
Why Hims & Hers Stock Could Be a Multi-Bagger in the Making
By Gabriel Osorio-Mazilli | June 24, 2025
View Why Hims & Hers Stock Could Be a Multi-Bagger in the Making

MU, REGN, and BIIB Company Descriptions

Biogen NASDAQ:BIIB

$132.62 -0.57 (-0.42%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$132.87 +0.25 (+0.18%)

As of 07/3/2025 04:57 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Micron Technology NASDAQ:MU

$122.02 +0.29 (+0.23%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$121.79 -0.23 (-0.19%)

As of 07/3/2025 04:59 PM Eastern

Micron Technology, Inc. designs, develops, manufactures, and sells memory and storage products worldwide. The company operates through four segments: Compute and Networking Business Unit, Mobile Business Unit, Embedded Business Unit, and Storage Business Unit. It provides memory and storage technologies comprising dynamic random access memory semiconductor devices with low latency that provide high-speed data retrieval; non-volatile and re-writeable semiconductor storage devices; and non-volatile re-writable semiconductor memory devices that provide fast read speeds under the Micron and Crucial brands, as well as through private labels. The company offers memory products for the cloud server, enterprise, client, graphics, networking, industrial, and automotive markets, as well as for smartphone and other mobile-device markets; SSDs and component-level solutions for the enterprise and cloud, client, and consumer storage markets; discrete storage products in component and wafers; and memory and storage products for the automotive, industrial, and consumer markets. It markets its products through its direct sales force, independent sales representatives, distributors, and retailers; and web-based customer direct sales channel, as well as through channel and distribution partners. Micron Technology, Inc. was founded in 1978 and is headquartered in Boise, Idaho.

Regeneron Pharmaceuticals NASDAQ:REGN

$545.00 -2.74 (-0.50%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$547.81 +2.81 (+0.52%)

As of 07/3/2025 04:57 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time